Drugs / LCAR-L10D
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03593109 | May 2019 → May 2021 | B-cell non-Hodgkin lymphoma | Second Affiliated Hospital of Xi'an Jiaotong University | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCAR-L10D | “This is a prospective, single-arm, single-center, open-label, single-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetics, and...” NCT03593109 ↗ |
| Action | Deplete | “The dual specificity CAR enables the T-cells to recognize and kill the tumor cell through recognition of CD19 and CD22.” NCT03593109 ↗ |
| Modality | Cell therapy | “patients will be treated with dual specificity CD19 and CD22 CAR-T cells” NCT03593109 ↗ |
| Route | Intravenous | “by intravenous injection” NCT03593109 ↗ |